drugset / Trial / NCT02638805
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-10
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 60 ug | — |
| Background | Liraglutide | Peptide | 1.2 mg | — |
| Background | Metformin | Small molecule | 1000 mg | — |